

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 15270J-004760US
Client Ref. No.: 209-US-CIP8B

Assistant Commissioner for Patents
Washington, D.C. 20231

On October 18, 2001

TOWNSEND and TOWNSEND and CREW LLP

Patricia J. Galli



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
JAN 15 2002
TECH CENTER 1600/2900

In re application of:

Schenk et al.

Application No.: 09/580,018

Filed: May 26, 2000

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

Examiner: Turner, Sharon

Art Unit: 1647

RESPONSE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This paper is submitted in response to the Office Action mailed September 24, 2001.

REMARKS

The Office Action mailed September 24, 2001 is a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. Applicants mailed a Communication Under 37 C.F.R.

§§ 1.821-1.825 and Preliminary Amendment to the USPTO on September 11, 2001, as evidenced by the attached return receipt postcard bearing the PTO OIPE date stamp of September 19, 2001. A PAIR report, attached, shows a pre-examination amendment was entered